Table 3.
Clinical course and treatment strategy.
| Variables | Non-cardiopulmonary failure (n = 70) | Cardiopulmonary failure (n = 44) | p value* |
|---|---|---|---|
| Life-threatening arrhythmia, n (%) | 2 (2.8) | 11 (25) | <0.01 |
| Cardiopulmonary resuscitation, n (%) | 1 (1.4) | 8 (18) | <0.01 |
| IABP, n (%) | 0 (0) | 1 (1) | 1.000 |
| Veno-arterial-ECMO, n (%) | 0 (0) | 2 (4.6) | 0.146 |
| Admission to ICU, length of stay | 2.4 ± 1.6 | 7.5 ± 9 | <0.01 |
| In-hospital death, n (%) | 1 (1.4) | 8 (18) | <0.01 |
| Thromboembolic events, n (%) | 8 (11.4) | 6 (13.6) | 0.72 |
| Acquired Long QTs, n (%) | 44 (63) | 29 (66) | 0.93 |
*p values for the comparison between classical group and adverse events group; ECMO, Extracorporal membrane oxygenation; IABP, Intraaortic balloon pump; ICU, Intermediate care unit.